# Fortress Biotech (FBIO) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/FBIO
## Company Profile
- Ticker: FBIO
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
## Stock Data
- Close: 2.09 USD
- Market cap: 88030540.8 USD
- Last updated: 2026-10-08
## Business Overview
### Multi-Asset Biopharmaceutical Holding Company
Fortress Biotech creates value by acquiring, forming, and advancing biopharmaceutical businesses and assets. Its portfolio includes commercial prescription products, development-stage programs, controlled subsidiaries, and minority investments across oncology, dermatology, and rare diseases.
### Decentralized Company-Building Model
Fortress frequently places individual assets within focused subsidiaries that can raise capital, form partnerships, or pursue strategic transactions independently. The parent company retains value through equity ownership, royalties, milestones, and other contractual economics.
### Rare Disease and Commercial Assets
Subsidiary Cyprium obtained FDA approval for ZYCUBO in Menkes disease and monetized the associated Rare Pediatric Disease Priority Review Voucher. Following Sun Pharma’s acquisition of Checkpoint, Fortress retains long-term royalty exposure to UNLOXCYT.
### Multiple Monetization Pathways
Fortress can realize value through commercial product revenue, subsidiary transactions, priority review vouchers, royalties, milestone payments, and retained equity interests. This structure means portfolio value may be created through regulatory success or strategic transactions at individual subsidiaries.
### Partnership-Sourced Pipeline
Fortress sources programs through collaborations with organizations including AstraZeneca, City of Hope, Nationwide Children’s Hospital, Columbia University, Dana-Farber, and Sentynl. Avenue’s acquisition of ATX-04 from Duke University adds a clinically validated program in Pompe disease.
## Why The Stock Is Moving

As of Oct 8, 2026, FBIO closed up 2.45% at $2.09. No new same-company headline was identified in the current news window.

## Future Catalysts

- Triplex clinical data in patients co-infected with HIV and cytomegalovirus by the end of 2026.
- Initiation of the MB-109 study in recurrent glioblastoma and high-grade astrocytoma in the fourth quarter of 2026.

## Drug Assets

- Emrosi

## Recent News
- 2026-09-08 20:05 EST — [Journey Medical Corporation to Participate in September 2026 Investor Conferences](https://biopharmsignal.com/news/FBIO/journey-medical-corporation-to-participate-in-september-2026-investor-conference-a4ce778b) — Source: Fortress Biotech
- 2026-09-08 12:00 EST — [Fortress Biotech to Present at the H.C. Wainwright 28th Annual Global Investment Conference](https://biopharmsignal.com/news/FBIO/fortress-biotech-to-present-at-the-h-c-wainwright-28th-annual-global-investment--48f53863) — Source: Fortress Biotech
- 2026-08-13 20:05 EST — [Fortress Biotech Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights](https://biopharmsignal.com/news/FBIO/fortress-biotech-reports-second-quarter-2026-financial-results-and-recent-corpor-5a84da12) — Source: Fortress Biotech
- 2026-08-12 20:01 EST — [Journey Medical Corporation Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights](https://biopharmsignal.com/news/FBIO/journey-medical-corporation-reports-second-quarter-2026-financial-results-and-re-b32c032d) — Source: Fortress Biotech
- 2026-08-05 12:30 EST — [Journey Medical Corporation to Announce Second Quarter 2026 Financial Results on August 12, 2026](https://biopharmsignal.com/news/FBIO/journey-medical-corporation-to-announce-second-quarter-2026-financial-results-on-03da3eb2) — Source: Fortress Biotech